Decision Diagnostics Corp. (DECN)
| Market Cap | 380.00 -99.0% |
| Revenue (ttm) | 2.13M -3.1% |
| Net Income | -8.29M |
| EPS | -0.02 |
| Shares Out | 380.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,000 |
| Average Volume | 99,340 |
| Open | 0.000001 |
| Previous Close | 0.000001 |
| Day's Range | 0.000001 - 0.000001 |
| 52-Week Range | 0.000001 - 0.0001 |
| Beta | -0.05 |
| RSI | 48.15 |
| Earnings Date | n/a |
About Decision Diagnostics
Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of d... [Read more]
Financial Performance
In 2020, Decision Diagnostics's revenue was $1.98 million, a decrease of -16.82% compared to the previous year's $2.38 million. Losses were -$29.67 million, 847.2% more than in 2019.
Financial StatementsNews
Decision Diagnostics Update
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their OptionsNew York, Ne...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Decision Diagnostics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $DECN #DECN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Decision Diagnostics Corp.
CEO charged in alleged COVID-19 fraud scheme
The Justice Department said late Friday that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 te...